Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma.
Twenty-one patients with disseminated malignant melanoma were treated with a combination of carboplatin and cytosine arabinoside. Two complete and three partial remissions occurred. No complete cross-resistance was found with a regimen containing 5-(dimethyltriazeno)imidazole-4-carboxamide (DTIC) in two patients. It is suggested that this regimen might be studied further as a second-line treatment for patients who fail on DTIC-containing treatment.
Mulder
N H
NH
Department of Internal Medicine, University Hospital Groningen, The Netherlands.
Sleijfer
D T
DT
de Vries
E G
EG
Schraffordt Koops
H
H
Willemse
P H
PH
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects; D003606:Dacarbazine / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects
D009944:Organoplatinum Compounds; D003561:Cytarabine; D003606:Dacarbazine; D016190:Carboplatin